Skip Nav Destination
Issues
15 July 2013
-
Cover Image
Cover Image
β-catenin is a transmembrane protein that associates with junctional proteins and assists with the maintenance of cell attachment. As revealed through immunofluorescent staining, β-catenin (shown in green) localizes to the cell membranes and within the lateral junctional complex in normal appendix tissue. In contrast, tissue samples from patients with pseudomyxoma peritonei display primarily cytoplasmic staining of β-catenin and virtually no staining at the intercellular boundaries. However, antibiotic treatment of patients with pseudomyxoma peritonei results in a significant increase in β-catenin within the cell membranes, appearing to aid in the renormalization of β-catenin distribution. For details, see the article by Semino-Mora and colleagues on page 3966 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Perspectives in Drug Approval
Molecular Pathways
Review
Human Cancer Biology
TH2 Cytokines from Malignant Cells Suppress TH1 Responses and Enforce a Global TH2 Bias in Leukemic Cutaneous T-cell Lymphoma
Emmanuella Guenova; Rei Watanabe; Jessica E. Teague; Jennifer A. Desimone; Ying Jiang; Mitra Dowlatshahi; Christoph Schlapbach; Knut Schaekel; Alain H. Rook; Marianne Tawa; David C. Fisher; Thomas S. Kupper; Rachael A. Clark
Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma
Jyotsna U. Rao; Udo F.H. Engelke; Richard J.T. Rodenburg; Ron A. Wevers; Karel Pacak; Graeme Eisenhofer; Nan Qin; Benno Kusters; Angelina G. Goudswaard; Jacques W.M. Lenders; Ad R.M.M. Hermus; Arjen R. Mensenkamp; Henricus P.M. Kunst; Fred C.G.J. Sweep; Henri J.L.M. Timmers
Cancer Therapy: Preclinical
Author Choice
Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy
Yi-Xiang Zhang; Jolieke G. van Oosterwijk; Ewa Sicinska; Samuel Moss; Stephen P. Remillard; Tom van Wezel; Claudia Bühnemann; Andrew B. Hassan; George D. Demetri; Judith V.M.G. Bovée; Andrew J. Wagner
PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer
Amanda Herzog; Yansong Bian; Robert Vander Broek; Bradford Hall; Jamie Coupar; Hui Cheng; Anastasia L. Sowers; John D. Cook; James B. Mitchell; Zhong Chen; Ashok B. Kulkarni; Carter Van Waes
Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
Emanuela Grassilli; Robert Narloch; Elena Federzoni; Leonarda Ianzano; Fabio Pisano; Roberto Giovannoni; Gabriele Romano; Laura Masiero; Biagio Eugenio Leone; Serena Bonin; Marisa Donada; Giorgio Stanta; Kristian Helin; Marialuisa Lavitrano
Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik; Bree Foley; Bin Zhang; Michael R. Verneris; Erica Warlick; Michelle K. Gleason; Julie A. Ross; Xianghua Luo; Daniel J. Weisdorf; Bruce Walcheck; Daniel A. Vallera; Jeffrey S. Miller
Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
Lana McClements; Anita Yakkundi; Angelos Papaspyropoulos; Hannah Harrison; Matthew P. Ablett; Puthen V. Jithesh; Hayley D. McKeen; Rachel Bennett; Christopher Donley; Adrien Kissenpfennig; Stuart McIntosh; Helen O. McCarthy; Eric O'Neill; Robert B. Clarke; Tracy Robson
Imaging, Diagnosis, Prognosis
Spinophilin Loss Correlates with Poor Patient Prognosis in Advanced Stages of Colon Carcinoma
Purificacion Estevez-Garcia; Iker Lopez-Calderero; Sonia Molina-Pinelo; Sandra Muñoz-Galvan; Ana Salinas; Lourdes Gomez-Izquierdo; Antonio Lucena-Cacace; Blanca Felipe-Abrio; Luis Paz-Ares; Rocio Garcia-Carbonero; Amancio Carnero
Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma
Wen-Wei Zhu; Jia-Jian Guo; Lei Guo; Hu-Liang Jia; Ming Zhu; Ju-Bo Zhang; Christopher A. Loffredo; Marshonna Forgues; Hua Huang; Xu-Jian Xing; Ning Ren; Qiong-Zhu Dong; Hai-Jun Zhou; Zheng-Gang Ren; Nai-Qing Zhao; Xin Wei Wang; Zhao-You Tang; Lun-Xiu Qin; Qing-Hai Ye
Cancer Therapy: Clinical
Antibiotic Treatment Decreases Microbial Burden Associated with Pseudomyxoma Peritonei and Affects β-Catenin Distribution
Cristina Semino-Mora; Traci L. Testerman; Hui Liu; Jeannette M. Whitmire; Kimberley Studeman; Yali Jia; Thomas J. McAvoy; Jennifer Francis; Carol Nieroda; Armando Sardi; D. Scott Merrell; Andre Dubois
Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens
Kimmie Ng; Josep Tabernero; Jimmy Hwang; Emilio Bajetta; Sunil Sharma; Salvatore A. Del Prete; Edward R. Arrowsmith; David P. Ryan; Michaela Sedova; Jin Jin; Kamel Malek; Charles S. Fuchs
Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer
Vered Stearns; Lisa K. Jacobs; MaryJo Fackler; Theodore N. Tsangaris; Michelle A. Rudek; Michaela Higgins; Julie Lange; Zandra Cheng; Shannon A. Slater; Stacie C. Jeter; Penny Powers; Susanne Briest; Calvin Chao; Carl Yoshizawa; Elizabeth Sugar; Igor Espinoza-Delgado; Saraswati Sukumar; Edward Gabrielson; Nancy E. Davidson
Letter to the Editor
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.